
L Glutathione Reduced (500mg) + L Ascorbic acid (250mg) + Tranexamic Acid (250mg)
Active composition
+2 more active ingredients
Tranexamic Acid inhibits plasminogen activation, preventing fibrinolysis and stabilizing blood clots.
Medical applications
Helga TX Tablet SR is a sustained-release formulation combining Tranexamic Acid (250 mg), L-Glutathione Reduced (500 mg), and L-Ascorbic Acid (250 mg), designed to provide synergistic therapeutic benefits primarily in dermatological and hemostatic applications. Tranexamic Acid, a synthetic antifibrinolytic agent, inhibits plasminogen activation, thereby reducing excessive bleeding and contributing to the management of hyperpigmentation disorders by modulating melanogenesis. L-Glutathione Reduced, a potent intracellular antioxidant, plays a critical role in neutralizing free radicals, enhancing cellular detoxification, and promoting skin lightening through its inhibitory effect on tyrosinase activity. L-Ascorbic Acid (Vitamin C) further supports antioxidant defense mechanisms, collagen synthesis, and skin repair processes, while also enhancing the efficacy of glutathione. The sustained-release mechanism ensures prolonged plasma concentration, optimizing therapeutic outcomes and improving patient compliance. Helga TX Tablet SR is indicated for the adjunctive treatment of melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities, as well as for conditions requiring antifibrinolytic intervention. It should be used under medical supervision, considering contraindications such as active thromboembolic disease or hypersensitivity. Regular monitoring is advised to evaluate therapeutic response and detect any adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Helga TX Tablet SR during pregnancy is not available. Please consult your doctor.
High Risk
Helga TX Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
There is limited information available on the use of Helga TX Tablet SR in patients with kidney disease. Please consult your doctor.
Exercise Caution
Helga TX Tablet SR may cause dizziness or weakness due to low blood pressure. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Helga TX Tablet SR in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Helga TX Tablet SR

Tranexamic Acid (250mg) + L Glutathione Reduced (500mg) + L Ascorbic acid (250mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+2 more active ingredients
Tranexamic Acid inhibits plasminogen activation, preventing fibrinolysis and stabilizing blood clots.
Medical applications
Helga TX Tablet SR is a sustained-release formulation combining Tranexamic Acid (250 mg), L-Glutathione Reduced (500 mg), and L-Ascorbic Acid (250 mg), designed to provide synergistic therapeutic benefits primarily in dermatological and hemostatic applications. Tranexamic Acid, a synthetic antifibrinolytic agent, inhibits plasminogen activation, thereby reducing excessive bleeding and contributing to the management of hyperpigmentation disorders by modulating melanogenesis. L-Glutathione Reduced, a potent intracellular antioxidant, plays a critical role in neutralizing free radicals, enhancing cellular detoxification, and promoting skin lightening through its inhibitory effect on tyrosinase activity. L-Ascorbic Acid (Vitamin C) further supports antioxidant defense mechanisms, collagen synthesis, and skin repair processes, while also enhancing the efficacy of glutathione. The sustained-release mechanism ensures prolonged plasma concentration, optimizing therapeutic outcomes and improving patient compliance. Helga TX Tablet SR is indicated for the adjunctive treatment of melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities, as well as for conditions requiring antifibrinolytic intervention. It should be used under medical supervision, considering contraindications such as active thromboembolic disease or hypersensitivity. Regular monitoring is advised to evaluate therapeutic response and detect any adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Helga TX Tablet SR during pregnancy is not available. Please consult your doctor.
High Risk
Helga TX Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
There is limited information available on the use of Helga TX Tablet SR in patients with kidney disease. Please consult your doctor.
Exercise Caution
Helga TX Tablet SR may cause dizziness or weakness due to low blood pressure. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Helga TX Tablet SR in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Helga TX Tablet SR















